Actively Recruiting

Phase Not Applicable
Age: 18Years - 85Years
All Genders
Healthy Volunteers
NCT06005298

Alcohol Misuse, Gut Microbial Dysbiosis and PrEP Care Continuum: Application and Efficacy of SBIRT Intervention

Led by Shirish S Barve · Updated on 2024-07-22

120

Participants Needed

1

Research Sites

220 weeks

Total Duration

On this page

Sponsors

S

Shirish S Barve

Lead Sponsor

N

National Institute on Alcohol Abuse and Alcoholism (NIAAA)

Collaborating Sponsor

AI-Summary

What this Trial Is About

This randomized control trial study among Pre-exposure prophylactic users (PrEP) aims to learn and determine the efficacy of Screening, brief intervention, and referral to treatment (SBRIT) in reducing the risk of alcohol use. The main questions it aims to answer are: 1. How alcohol use impacts the PrEP continuum and to understand how early intervention and treatment approach affects alcohol use and PrEP adherence. 2. Investigate the effectiveness of the SBIRT intervention in preventing hazardous alcohol use and its impact on gut dysbiosis in PrEP users. 3. To determine alterations in the gut microbiome (dysbiosis), intestinal homeostasis, systemic inflammation, and markers of liver disease associated with hazardous alcohol use among PrEP users.

CONDITIONS

Official Title

Alcohol Misuse, Gut Microbial Dysbiosis and PrEP Care Continuum: Application and Efficacy of SBIRT Intervention

Who Can Participate

Age: 18Years - 85Years
All Genders
Healthy Volunteers

Eligibility Criteria

Eligible

You may qualify if you...

  • Age between 18 and 85 years
  • Confirmed negative status for HIV, Hepatitis B, and Hepatitis C
  • Current user of Pre-Exposure Prophylaxis (PrEP)
  • Able to speak English or Spanish
  • Cognitively able to provide informed consent
  • Receiving care at a participating healthcare facility
Not Eligible

You will not qualify if you...

  • Unable to provide informed consent
  • Diagnosed with a major psychiatric illness
  • Having unstable medical conditions such as cancer
  • Taking immunosuppressant medications or undergoing chemotherapy
  • Using daily antibiotics or probiotics
  • Having severe gastrointestinal or liver diseases
  • Having autoimmune diseases

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

University of Louisville

Louisville, Kentucky, United States, 40202

Actively Recruiting

Loading map...

Research Team

A

Andrea Reyes Vega, MD, MSc

CONTACT

V

Vania Remenik, MD

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

PREVENTION

Number of Arms

3

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here